Surgery and OncologySurgery and OncologyХирургия и онкология2949-5857Publishing House ABV Press26510.17650/2220-3478-2018-8-4-34-46LITERATURE REVIEWОБЗОР ЛИТЕРАТУРЫNew therapeutic agents for metastatic colorectal cancer: literature reviewНовые препараты в лечении метастатического колоректального рака: обзор литературыZabelinM. V.ЗабелинМ. В.
Russian Federation

3 2ndBotkinskiy Proezd, Moscow 125284.

Забелин Максим Васильевич.

125284, Москва, 2-й Боткинский проезд, 3.

 

maximzabelin@mail.ruGordeevS. S.ГордеевС. С.

Russian Federation

24 Kashirskoe Shosse, Moscow 115478.

115478, Москва, Каширское шоссе, 24.

KochkinaS. O.КочкинаС. О.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478.

115478, Москва, Каширское шоссе, 24.

KostinA. A.КостинА. А.
Russian Federation

3 2ndBotkinskiy Proezd, Moscow 125284.

125284, Москва, 2-й Боткинский проезд, 3.

FedenkoA. A.ФеденкоА. А.
Russian Federation

3 2nd Botkinsky Proezd, Moscow 125284.

125284, Москва, 2-й Боткинский проезд, 3.

PetrovL. O.ПетровЛ. О.
Russian Federation

4Koroleva St., Obninsk 249036.

249036, Обнинск, ул. Королева, 4.

GameevaE. V.ГамееваЕ. В.
Russian Federation

3 2nd Botkinsky Proezd, Moscow 125284.

125284, Москва, 2-й Боткинский проезд, 3.

National Medical Research Radiology Center, Ministry of Health of RussiaНациональный медицинский исследовательский центр радиологии Минздрава РоссииN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaНациональный медицинский исследовательский центр онкологии им. Н.Н. Блохина Минздрава РоссииP.A. Herzen Moscow Oncology Research Institute — branch of the National Medical Radiology Research Center, Ministry of Health of RussiaМосковский научно-исследовательский онкологический институт им. П.А. Герцена — филиал ФГБУ«Национальный медицинский исследовательский центр радиологии» Минздрава РоссииA.F. Tsyb Medical Radiological Research Center — branch of the National Medical Research Radiology Center, Ministry of Health of RussiaМедицинский радиологический научный центр им А.Ф. Цыба — филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России271220188434462712201827122018Copyright ©; 2018, Zabelin M.V., Gordeev S.S., Kochkina S.O., Kostin A.A., Fedenko A.A., Petrov L.O., Gameeva E.V.Copyright ©; 2018, Забелин М.В., Гордеев С.С., Кочкина С.О., Костин А.А., Феденко А.А., Петров Л.О., Гамеева Е.В.2018Zabelin M.V., Gordeev S.S., Kochkina S.O., Kostin A.A., Fedenko A.A., Petrov L.O., Gameeva E.V.Забелин М.В., Гордеев С.С., Кочкина С.О., Костин А.А., Феденко А.А., Петров Л.О., Гамеева Е.В.https://creativecommons.org/licenses/by/4.0https://onco-surgery.info/jour/article/view/265

This article provides an overview of drugs for metastatic colorectal cancer that are currently being evaluated in clinical trials. We discuss possible drug combinations and outlooks of their use in different lines of therapy. In addition to VEGF and EGFR inhibitors, we describe the molecules with fundamentally new mechanisms of action that can significantly expand the list of anticancer agents and increase the number of possible lines of therapy.

В статье представлен обзор препаратов для лечения метастатического колоректального рака, находящихся в фазе клинических исследований. Представлены данные о возможных комбинациях, перспективах использования в различных линиях терапии. Помимо новых вариантов ингибиторов VEGFи EGFRрассматриваются молекулы с принципиально новыми механизмами действия, которые могут значительно расширить арсенал лекарственного лечения и потенциально увеличить число возможных линий терапии.

colorectal cancerchemotherapytargeted drugsEGFR inhibitorsVEGF inhibitorsколоректальный ракхимиотерапиятаргетные препаратыингибиторы EGFRингибиторы VEGFLukashina M.I., Smirnova A.V., Aliev V.A. et al. Dendritic cell vaccines for colorectal cancer therapy. Vestnik RONC im. N.N. Blokhina RAMN = Journal of N.N. Blokhin Russian Cancer Research Center 2008;19(3):35–42. (In Russ.).Лукашина М.И., Смирнова А.В., Алиев В.А. и др. Дендритные вакцины в терапии колоректального рака. Вестник РОНЦ им. Н.Н. Блохина РАМН 2008;19(3):35–42.Akylbekova G.A., Abdylaev G.A. Current possibilities of chemotherapy for colorectal cancer (literature review). Izvestiya vuzov = Proceedings of Universities 2013;5:53–7. (In Russ.).Акылбекова Г.А., Абдылаев Г.А. Современные возможности химиотерапии колоректального рака (обзор литературы). Известия вузов 2013;5:53–7.Smagulova K. Assessing quality of life in patients treated for metastatic colon and rectal cancer. Uspekhi sovremennoy nauki = Advances of Modern Science 2017;1(6):81–3. (In Russ.).Смагулова К. Оценка качества жизни при лечении метастатического рака толстой и прямой кишок. Успехи современной науки 2017;1(6):81–3.Fedyanin M.Yu., Tryakin A.A., Tjulandin S.A. Targeted drugs in the treatment of colon cancer. Onkologiya, gematologiya i radiologiya = Oncology, Hematology, and Radiology 2012;3:30–6. (In Russ.).Федянин М.Ю., Трякин А.А., Тюляндин С.А. Таргетные препараты в терапии рака толстой кишки. Онкология, гематология и радиология 2012;3:30–6.Hoff P.M., Ansari R., Batist G. et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19(8):2282–92. PMID: 11304782. DOI: 10.1200/JCO.2001.19.8.2282.Hoff P.M., Ansari R., Batist G. et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19(8):2282–92. PMID: 11304782. DOI: 10.1200/JCO.2001.19.8.2282.Colucci G., Gebbia V., Paoletti G. et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol 2005;23(22):4866–75. PMID: 15939922. DOI: 10.1200/JCO.2005.07.113.Colucci G., Gebbia V., Paoletti G. et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol 2005;23(22):4866–75. PMID: 15939922. DOI: 10.1200/JCO.2005.07.113.Díaz-Rubio E., Tabernero J., Gómez-España A. et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 2007;25(27):4224–30. PMID: 17548839. DOI: 10.1200/JCO.2006.09.8467.Díaz-Rubio E., Tabernero J., Gómez-España A. et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 2007;25(27):4224–30. PMID: 17548839. DOI: 10.1200/JCO.2006.09.8467.Kuipers E.J., Grady W.M., Lieberman D. et al. Colorectal cancer. Nat Rev Dis Primers 2015;1:15065.Tryakin A.A. Targeted therapy for colorectal, gastric, and pancreatic cancer. Prakticheskayaonkologiya = Practical Oncology 2010;11(3):143—50. (In Russ.).Трякин А.А. Таргетная терапия колоректального рака, рака желудка и поджелудочной железы. Практическая онкология 2010;11(3):143–50.Amado R.G., Wolf M., Peeters M. et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26(10):1626—34. PMID: 18316791. DOI: 10.1200/JCO.2007.14.7116.Douillard J.Y., Oliner K.S., Siena S. et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369(11):1023—34. PMID: 24024839. DOI: 10.1056/NEJ-Moa1305275.Bokemeyer C., Bondarenko I., Makhson A. et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-71. PMID: 19114683. DOI: 10.1200/JCO.2008.20.8397.Susman E. Rash correlates with tumour response after cetuximab. Lancet Oncol 2004;5(11):647. PMID: 15536688.Van Cutsem E., Kohne C.H., Hitre E. et al. Cetuximab and chemotherapy as ini¬tial treatment for metastatic colorectal cancer. N Engl J Med 2009;360(14): 1408-17. PMID: 19339720. DOI: 10.1056/NEJMoa0805019.Vladimirova L.Yu., Abramova N.A., Storozhakova A.E. Targeted therapy with anti-EGFR-monoclonal antibodies for colorectal cancer. Zlokachestvennye opukholi = Malignant Tumors 2016;4( special issue 1):87—91. (In Russ.).Владимирова Л.Ю., Абрамова Н.А., Сторожакова А.Э. Таргетная терапия аши-EGFR-моноклональными антителами в лечении колоректального рака. Злокачественные опухоли 2016;4(спецвыпуск 1):87—91.Gorchakov S.V., Pravosudov I.V., Vasilyev S.V. et al. Multidisciplinary approach to the treatment of colorectal cancer with liver metastases: oncologist's view. Povolzhskiy onkologicheskiy vestnik = Oncology Bulletin of the Volga Region 2015;4;70—8. (In Russ.).Горчаков С.В., Правосудов И.В., Васильев С.В. и др. Мультидисциплинарный подход в лечении больных колоректальным раком с метастазами в печень — взгляд онколога сегодня. Поволжский онкологический вестник 2015;4;70—8.Gorchakov S.V., Pravosudov I.V., Vasilyev S.V. et al. Current approaches to the treatment of colorectal cancer with liver metastases: literature review. Vestnik SPbGU = Bulletin of Saint Petersburg University 2015;11(3):55—68. (In Russ.).Горчаков С.В., Правосудов И.В., Васильев С.В. и др. Современные подходы к лечению больных колоректальным раком с метастазами в печень: обзор литературы. Вестник СПбГУ 2015;11(3):55—68.Burqdorf S.K. Dendritic cell vaccination of patients with metastatic colorectal cancer. Dan Med Bull 2010;57(9):B4171. PMID: 20816019.Burris H.A., Infante J.R., Ansell S.M. et al. Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, in patients with advanced solid tumors. J Clin Oncol 2017;35(18):2028—36. PMID: 28463630. DOI: 10.1200/JCO.2016.70.1508.Elez E., Hendlisz A., Delaunoit T. et al. Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or meta¬static colorectal cancer. Br J Cancer 2016;114:372—80. PMID: 26766738. DOI: 10.1038/bjc.2015.480.Artamonova E.V. Cetuximab in the treatment of metastatic colorectal cancer: skin toxicity and methods to address it. Onkologicheskaya koloproktologiya = Colorectal Oncology 2011;3:21—7. (In Russ.).Артамонова Е.В. Цетуксимаб в терапии метастатического колоректального рака толстой кишки: кожная токсичность и пути решения проблемы. Онкологическая колопроктология 2011;3:21—7.Dobrova N.V. Cetuximab in the treatment of metastatic colorectal cancer. Onkologiya, gematologiya i radiologiya = Oncology, Hematology, and Radiology 2012;2:24—9. (In Russ.).Доброва Н.В. Цетуксимаб в лечении метастатического колоректального рака. Онкология, гематология и радиология 2012;2:24—9.Perevodchikova N. Targeted drugs and their role in cancer treatment. Klinicheskaya onkogematologiya = Clinical Oncohematology 2009;2(4):367—73. (In Russ.).Переводчикова Н.И. Таргетные препараты и их место в современной терапии опухолевых заболеваний. Клиническая онкогематология 2009;2(4):367—73.Sobrero A.F., Maurel J., Fehrenbacher L. et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with meta¬static colorectal cancer. J Clin Oncol 2008;26(14):2311—9. PMID: 18390971. DOI: 10.1200/JCO.2007.13.1193.Karapetis C.S., Khambata-Ford S., Jonker D.J. et al. KRAS mutations and be-nefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359(17):1757—65. PMID: 18946061. DOI: 10.1056/NEJMoa0804385.Vorontsova K.A., Dobrova N.V., Vyshinskaya G.V. Second-line anticancer therapy for metastatic colorectal cancer: treatment strategy. Meditsinskiy sovet = Medical Council 2015;8:55—9. (In Russ.).Воронцова К.А., Доброва Н.В., Вышинская Г.В. Вторая линия противоопухолевой терапии метастатического колоректального рака: стратегия лечения. Медицинский совет 2015;8:55—9.Vorontsova K.A., Chernoglazova E.V., Vyshinskaya G.V. Targeted drugs in second-line therapy for disseminated colorectal cancer. Meditsinskiy sovet = Medical Council 2015;8:91—6. (In Russ.).Воронцова К.А., Черноглазова Е.В., Вышинская Г.В. Таргетные препараты во второй линии противоопухолевой терапии диссеминированного колоректального рака. Медицинский совет 2015;8:91—6.Kuznetsova O.M., Khadasheva Z.S., Smirnova I.P. Vascular endothelial growth factor inhibitors and tyrosine kinase receptor inhibitors as new antiangiogenic agents for anticancer therapy. Vestnik Chechenskogo gosudarstvennogo universiteta = Bulletin of the Chechen State University 2007;4(24):60—6. (In Russ.).Кузнецова О.М., Хадашева З.С., Смир-нова И.П. Ингибиторы фактора роста эндотелия сосудов и тирозинкиназных рецепторов как направление антиангиогенной терапии опухолей. Вестник Чеченского государственного университета 2007;4(24):60—6.Feoktistova P.S., Zaginayko A.V., Karaseva V.V., Khaylenko V.A. Targeted therapy for metastatic colorectal cancer. Zdravookhranenie Yugry: opyt i innovatsii = Health Care in Ugra: Experience and Innovations 2016;C:76—84. (In Russ.).Феоктистова П.С., Загинайко А.В., Карасева В.В., Хайленко В.А. Таргетная терапия метастатического колоректального рака. Здравоохранение Югры: опыт и инновации 2016;C:76—84.Price T.J., Peeters M., Kim T.W. et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 2014;15(6):569—79. PMID: 24739896. DOI: 10.1016/S1470-2045(14)70118-4.Douillard J.Y., Siena S., Cassidy J. et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 2014;25(7):1346—55. PMID: 24718886. DOI: 10.1093/annonc/mdu141.Douillard J.Y., Siena S., Cassidy J. et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of met¬astatic colorectal cancer. Ann Oncol 2014;25(7):1346—55. PMID: 24718886. DOI: 10.1093/annonc/mdu141.Safety study of GC1118 (Recombinant Human Anti-EGFR Antibody) in patients with advanced solid cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT02352571?cond=GC1118&rank=1.Safety study of GC1118 (Recombinant Human Anti-EGFR Antibody) in patients with advanced solid cancer. Available at: https://clinicaltrials.gov/ct2/show/ NCT02352571?cond=GC1118&rank=1.Gan H.K., Seruga B., Knox J.J. Sunitinib in solid tumors. Expert Opin Investig Drugs 2009;18(6):821—34. DOI: 10.1517/13543780902980171.Zhou J., Lin Sh., Jing G. A dose escala-tion study of nimotuzumab plus irinotecan as second-line treatment in metastatic colorectal cancer with wild-type KRAS. J Clin Oncol 2012:30(15 suppl):e14122. DOI: 10.1200/jco.2012.30.15_suppl.e14122.Zhou Y., Shen L., Zheng J. P50 dose-es-calation study of nimotuzumab plus irinotecan as second-line treatment in meta static colorectal cancer with wild-type KRAS. EJC Supplements 2011;9:20.Dienstmann R., Patnaik A., Garcia-Carbonero R. et al. Safety and activity of the first-in-class Sym004 anti-EGFR antibody mixture in patients with refrac-tory colorectal cancer. Cancer Discov 2015;5(6):598—609. DOI: 10.1158/2159-8290.CD-14-1432.Lynch D., Murphy A. The emerging role of immunotherapy in colorectal cancer. Ann Transl Med 2016;4(16):305. DOI: 10.21037/atm.2016.08.29.Stanculeanu D.L., Daniela Z., Lazescu A. et al. Development of new immunotherapy treatments in different cancer types. J Med Life 2016;9(3):240-8. PMID: 27974927.Becerra A.Z., Probst P., Tejani M.A. et al. Evaluating the prognostic role of elevated preoperative carcinoembryonic antigen levels in colon cancer patients: results from the national cancer database. Ann Surg Oncol 2016;23(5):1554—61. PMID: 26759308. DOI: 10.1245/s10434-015-5014-1.Hurwitz H., Fehrenbacher L., Novotny W. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42. PMID: 15175435. DOI: 10.1056/NEJMoa032691.Liu K.-J., Chao T.-Y., Chang J.-Y. et al. A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment. J Biomed Sci 2016;23(1):1—11. PMID: 27558635. DOI: 10.1186/s12929-016-0279-7.Cremolini C., Loupakis F., Antoniotti C. et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015;16(13):1306-15. PMID: 26338525. DOI: 10.1016/S1470-2045(15)00122-9.Oki E., Kato T., Bando H. et al. A multi-center clinical phase II study of FOLFOX-IRI plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: QUATTRO study. Clin Colorectal Cancer 2018;17(2):147-55. PMID: 29530335. DOI: 10.1016/j.clcc.2018.01.011.Giantonio B.J., Catalano P.J., Meropol N.J. et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25(12):1539—44. PMID: 17442997. DOI: 10.1200/JCO.2006.09.6305.Yamaguchi K., Taniguchi H., Komori A. et al. A single-arm phase II trial of com-bined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pretreated patients with metastatic colorectal cancer. BMC Cancer 2015;15:601. PMID: 26311588. DOI: 10.1186/s12885-015-1606-1.Yakusheva T.A., Kogoniya L.M., Fedotov A.Yu. et al. Avastin in the treatment of metastatic colorectal cancer. Rossiyskiy bioterapevtycheskiy zhurnal = Russian Biotherapeutic Journal 2010;4(9):35—8. (In Russ.).Якушева Т.А., Когония Л.М., Федо¬тов А.Ю. и др. Авастин в лечении метастатического колоректального рака. Российский биотерапевтический журнал 2010;4(9):35—8.Mikhaylova N.V., Fayrushina A.N. Current approach to colorectal cancer therapy. Targeted therapy for metastatic colorectal cancer. Povolzhskiy onkologicheskiy vestnik = Oncology Bulletin of the Volga Region 2016;3(25):80—4. (In Russ.).Михайлова Н.В., Файрушина А.Н. Современный подход к терапии коло-ректального рака. Таргетная терапия метастатического колоректального рага. Поволжский онкологический вестник 2016;3(25):80—4.Ciprotti M., Tebbutt N.C., Lee F.T. et al. Phase I imaging and pharmacodynamic trial of CS-1008 in patients with metastat¬ic colorectal cancer. J Clin Oncol 2015;33(24):2609—616. PMID: 26124477. DOI: 10.1200/JCO.2014.60.4256.Amin M. The potential role of immuno-therapy to treat colorectal cancer. Exp Opin Investig Drugs 2015;(3):329—44. PMID: 25519074. DOI: 10.1517/13543784.2015.985376.Van Cutsem E., Tabernero J., Lakomy R. et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;30(28):3499—506. PMID: 22949147. DOI: 10.1200/JCO.2012.42.8201.Ruff P., van Cutsem E., Lakomy R. et al. Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial. J Geriatr Oncol 2018;9(1):32—9. PMID: 28807738. DOI: 10.1016/j.jgo.2017.07.010.Pastorino A., Di Bartolomeo M., Maiello E. et al. Aflibercept plus FOLFIRI in the real-life setting: safety and quality of life data from the italian patient cohort of the aflibercept safety and quality-of-life program study. Clin Colorectal Cancer 2018. PII: S1533-0028(18)30050-1.Bordonaro R., Sobrero A.F., Frassineti L. et al. Ziv-aflibercept in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety data from the global aflibercept safety and quality-of-life program (ASQoP and AFEQT studies) in patients >65. J Clin Oncol 2014;1:545.Likhova E.A., Yukalchuk D.Yu., Ponomarenko D.M., Shevchuk A.V. Aflibercept in second-line therapy for metastatic colorectal cancer: clinical experience. Effektivnaya farmakoterapiya = Effective Pharmacotherapy 2017;20:38-40. (In Russ.).Лихова Е.А., Юкальчук Д.Ю., Пономаренко Д.М., Шевчук А.В. Клинический опыт применения препарата афлиберцепт во второй линии терапии метастатического колоректального рака. Эффективная фармакотерапия 2017;20:38-40.Segelov E., Chan D., Shapiro J. et al. The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomized trials. Br J Cancer 2014;111(6):1122-31. PMID: 25072258.Francoso A., Simioni P.U. Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies. Drug Des Devel Ther 2017;11:177-84. PMID: 28138221. DOI: 10.2147/DDDT.S119036.Lin E.H. A randomized, phase II study of the anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal anti-body robatumumab (SCH 717454) in patients with advanced colorectal cancer. Cancer Med 2014;3(4):988—97. PMID: 24905030. DOI: 10.1002/cam4.263.Patnaik A., LoRusso P.M., Messersmith WA. et al. Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors. Cancer Chenother Pharmacol 2014;73(5):951—60. PMID: 24633809. DOI: 10.1007/s00280-014-2426-8.Weekes C.D. A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors. Invest New Drugs 2014;32(4):653—60. PMID: 24604265.Fedyanin M.Yr., Tryakin AA, Tjulandin S.Yu. Potential predictors of the efficacy of anti-EGFR therapy in metastatic colon cancer. Onkologicheskaya proktologiya = Proctologic Oncology 2013;2:21-30. (In Russ.).Федянин М.Ю., Трякин А.А., Тюляндин С.Ю. Потенциальные предикторы эффективности анти-EGFR-терапии при метастатическом раке толстой кишки. Онкологическая проктология 2013;2:21-30.Sekacheva M.I. Regorafenib: new drug for metastatic colorectal cancer. Zlokachestvennye opukholi = Malignant Tumors 2016;2(18):69—76. (In Russ.).Секачева М.И. Регорафениб: новый препарат для лечения метастатического колоректального рака. Злокачественные опухоли 2016;2(18):69—76.Ohhara Y., Fukuda N., Takeuchi S. et al. Role of targeted therapy in metastatic colorectal cancer. World J Gastrointest Oncol 2016;8(9):642-55.Yoshino T., Komatsu Y., Yamada Y. et al. Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and nonJapanese subpopulations. Invest New Drugs 2015;33(3):740—50. PMID: 25213161. DOI: 10.1007/s10637-014-0154-x.Goel G. Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a “me too” drug? Cancer Manag Res 2018;10:425-37. PMID: 29563833. DOI: 10.2147/CMAR.S88825.Korytova L.I., Tarazov P.G., Gopta E.V., Polikarpov A.A. Radiotherapy in the combination treatment of colorectal cancer with liver metastases. Palliativnaya meditsina i reabilitatsiya = Palliative Care and Rehabilitation 2009;3:27-30. (In Russ.).Корытова Л.И., Таразов П.Г., Гопта Е.В., Поликарпов А.А. Лучевая терапия в комбинированном лечении метастазов колоректального рака в печень. Паллиативная медицина и реабилита-ция 2009;3:27-30.Lassen U.N., Meulendijks D., Siu L.L. et al. A phase I monotherapy study of RG7112, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers. Clin Cancer Res 2015;21(2):258-66.Clinical Study Report CS1008-A-E203. Version 1.0, 2012. 7 p.Rocha Lima C.M., Bayraktar S., Flores A.M. et al. Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with meta-static colorectal cancer. Cancer Invest 2012;30(10):727—31. PMID: 23061802. DOI: 10.3109/07357907.2012.732163.Bendell J.C., Lenz H.J., Ryan T. et al. Phase 1/2 study of KRN330, a fully hu-man anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer. Invest New Drugs 2014;32(4):682-90. PMID: 24691674. DOI: 10.1007/s10637-014-0088-3.Infante J.R., Bendell J.C., Goff L.W. et al. Safety, pharmacokinetics and pharmaco-dynamics of the anti-A33 fully-human monoclonal antibody, KRN330, in patients with advanced colorectal cancer. Eur J Cancer 2013;49(6):1169—75. PMID: 23294608. DOI: 10.1016/j.ejca.2012.11.033.Deming D.A., Cavalcante L.L., Lubner S.J. et al. A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer. Invest New Drugs 2016;34(2):168-75. PMID: 26666244. DOI: 10.1007/s10637-015-0314-7.Sobrero A.F., Bordonaro R., Bencardino K. et al. Zivaflibercept (Z) in combi-nation with FOLFIRI for second-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Interim safety data from the global Aflibercept Safety and Quality-of-Life Program in pts pretreated with bevacizumab (B). J Clin Oncol 2015;3:528. DOI: 10.1200/jco.2015.33.3_suppl.528.